AbCheck s r o, a Czech-based company specializing in the discovery and development of novel human high affinity antibodies, announced today an antibody discovery deal with Eli Lilly and Company.
Under the agreement, AbCheck will use its three antibody discovery libraries to deliver high-affinity, fully human antibodies against an undisclosed number of Lilly targets. The three distinct human antibody libraries comprise a total of about 10 billion sequentially and structurally diverse antibodies. Lilly, which has full rights to any antibodies selected, will pay AbCheck discovery fees and development milestone payments. Other financial and deal terms are not disclosed.
"This discovery deal with Lilly is an important validation of our antibody discovery and business approach," said Dr Volker Lang, Managing Director of AbCheck. "Signing our first deal with such a significant company so soon after setting up AbCheck, has certainly given us a tremendous boost of confidence that AbCheck is following a successful business strategy."
AbCheck's libraries are designed as universal tools for the isolation of antibodies against all possible targets. This breadth of targets differentiates the libraries from immunized libraries, which are restricted to only a minor fraction of therapeutically interesting target antigens.
AbCheck s r o
